JP6546587B2 - 線維性疾患を処置するためのエンドグリンポリペプチド - Google Patents

線維性疾患を処置するためのエンドグリンポリペプチド Download PDF

Info

Publication number
JP6546587B2
JP6546587B2 JP2016526141A JP2016526141A JP6546587B2 JP 6546587 B2 JP6546587 B2 JP 6546587B2 JP 2016526141 A JP2016526141 A JP 2016526141A JP 2016526141 A JP2016526141 A JP 2016526141A JP 6546587 B2 JP6546587 B2 JP 6546587B2
Authority
JP
Japan
Prior art keywords
eng
amino acid
seq
pharmaceutical composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016526141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535741A5 (enExample
JP2016535741A (ja
Inventor
グリンベルグ，アーシャ
カストンガイ，ロザリン
ワーナー，エリック
クマール，ラビンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of JP2016535741A publication Critical patent/JP2016535741A/ja
Publication of JP2016535741A5 publication Critical patent/JP2016535741A5/ja
Application granted granted Critical
Publication of JP6546587B2 publication Critical patent/JP6546587B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016526141A 2013-10-25 2014-10-24 線維性疾患を処置するためのエンドグリンポリペプチド Expired - Fee Related JP6546587B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361896002P 2013-10-25 2013-10-25
US61/896,002 2013-10-25
PCT/US2014/062147 WO2015061666A1 (en) 2013-10-25 2014-10-24 Endoglin peptides to treat fibrotic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019115063A Division JP6994481B2 (ja) 2013-10-25 2019-06-21 線維性疾患を処置するためのエンドグリンポリペプチド

Publications (3)

Publication Number Publication Date
JP2016535741A JP2016535741A (ja) 2016-11-17
JP2016535741A5 JP2016535741A5 (enExample) 2017-11-30
JP6546587B2 true JP6546587B2 (ja) 2019-07-17

Family

ID=51894230

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016526141A Expired - Fee Related JP6546587B2 (ja) 2013-10-25 2014-10-24 線維性疾患を処置するためのエンドグリンポリペプチド
JP2019115063A Expired - Fee Related JP6994481B2 (ja) 2013-10-25 2019-06-21 線維性疾患を処置するためのエンドグリンポリペプチド
JP2021201819A Pending JP2022058352A (ja) 2013-10-25 2021-12-13 線維性疾患を処置するためのエンドグリンポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019115063A Expired - Fee Related JP6994481B2 (ja) 2013-10-25 2019-06-21 線維性疾患を処置するためのエンドグリンポリペプチド
JP2021201819A Pending JP2022058352A (ja) 2013-10-25 2021-12-13 線維性疾患を処置するためのエンドグリンポリペプチド

Country Status (9)

Country Link
US (2) US20150202260A1 (enExample)
EP (2) EP3060235B1 (enExample)
JP (3) JP6546587B2 (enExample)
KR (2) KR20220013459A (enExample)
CN (1) CN105899225A (enExample)
AU (2) AU2014339898B2 (enExample)
CA (1) CA2928708A1 (enExample)
EA (2) EA202090707A1 (enExample)
WO (1) WO2015061666A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
CA2833747C (en) 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
EP3060235B1 (en) 2013-10-25 2020-12-02 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
TN2017000417A1 (en) * 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CA3029890A1 (en) * 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
CN106994181A (zh) * 2017-03-10 2017-08-01 上海交通大学医学院附属第九人民医院 Bmp9在制备延缓肝纤维化药物中的应用
TW202019476A (zh) * 2018-07-26 2020-06-01 日商參天製藥股份有限公司 伴隨視網膜纖維化之眼部疾病之藥劑
WO2022075756A1 (ko) * 2020-10-08 2022-04-14 주식회사 큐롬바이오사이언스 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물
KR20240167591A (ko) * 2023-05-18 2024-11-27 한국과학기술연구원 항-엔도글린 항체 및 이의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
CZ291047B6 (cs) 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
CA2147754A1 (en) 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100856995B1 (ko) 1997-04-07 2008-09-04 제넨테크, 인크. 인간화 항체 및 인간화 항체의 제조 방법
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
MEP13708A (en) 2000-06-23 2010-06-10 Bayer Schering Pharma Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
PL1638941T3 (pl) 2003-05-22 2010-11-30 Abbvie Bahamas Ltd Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
RS20181002A1 (sr) 2003-05-30 2018-12-31 Genentech Inc Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20090286271A1 (en) 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
WO2007143023A1 (en) 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
ES2612755T3 (es) 2006-11-02 2017-05-18 Acceleron Pharma, Inc. Antagonistas de receptor y ligando de ALK1 y usos de los mismos
WO2008151078A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
EP2209003A1 (en) * 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US20100210713A1 (en) * 2009-01-16 2010-08-19 The General Hospital Corporation Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
CN102548617B (zh) * 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
US20120183543A1 (en) * 2009-05-08 2012-07-19 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US8795663B2 (en) 2010-01-12 2014-08-05 Beth Israel Deaconess Medical Center, Inc. Soluble endoglin and uses thereof
CA2833747C (en) * 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
EP2739645B1 (en) * 2011-08-01 2018-12-19 Tufts Medical Center, Inc. Endoglin-specific antibody for use in a method of treating heart failure and related conditions
US10214590B2 (en) 2013-09-20 2019-02-26 Tufts Medical Center, Inc. Inhibitors of endoglin activity for the treatment of fibrosis
EP3060235B1 (en) 2013-10-25 2020-12-02 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof

Also Published As

Publication number Publication date
US20200164029A1 (en) 2020-05-28
EA201690855A1 (ru) 2016-10-31
EP3851118A1 (en) 2021-07-21
KR102354787B1 (ko) 2022-01-24
WO2015061666A1 (en) 2015-04-30
CA2928708A1 (en) 2015-04-30
AU2020244463A1 (en) 2020-10-29
AU2014339898B2 (en) 2020-07-23
AU2014339898A1 (en) 2016-05-26
KR20220013459A (ko) 2022-02-04
EP3060235A1 (en) 2016-08-31
US20150202260A1 (en) 2015-07-23
JP2022058352A (ja) 2022-04-12
JP2016535741A (ja) 2016-11-17
EA035481B1 (ru) 2020-06-23
US11590201B2 (en) 2023-02-28
CN105899225A (zh) 2016-08-24
EA202090707A1 (ru) 2020-12-30
EP3060235B1 (en) 2020-12-02
JP2019196364A (ja) 2019-11-14
JP6994481B2 (ja) 2022-02-04
KR20160066553A (ko) 2016-06-10

Similar Documents

Publication Publication Date Title
JP7097930B2 (ja) エンドグリンポリペプチドおよびその使用
JP6546587B2 (ja) 線維性疾患を処置するためのエンドグリンポリペプチド
US20210002342A1 (en) Bmprii polypeptides and uses thereof
HK40055818A (en) Endoglin peptides to treat fibrotic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190522

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190621

R150 Certificate of patent or registration of utility model

Ref document number: 6546587

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees